

DO I NEED CHEMOTHERAPY?

The Oncotype DX Breast Recurrence Score[®] test is proven to predict the benefit of chemotherapy.

Your Diagnosis

You've been diagnosed with stage I-IIIa hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer.

Your Treatment Choices

Now, you have treatment choices to make. How will your tumor respond to treatment? Do you need chemotherapy?

Get Personalized Insights

Your doctor has ordered the Oncotype DX Breast Recurrence Score test to help answer these questions, which can help you and your doctor personalize your treatment plan.

“Now that I have gone through my journey, I am passionate about helping breast cancer patients make informed treatment decisions.”

PUNITA K.
Breast cancer
survivor and
Oncotype DX[®]
Ambassador

Sample report for node-negative patient inside.



Is chemotherapy right for you?

Only the Oncotype DX Breast Recurrence Score[®] genomic test can predict chemotherapy benefit.^{1,2}



Get Personalized Insights for Your Treatment

Just as every patient is different, so is every tumor. The Breast Recurrence Score[®] test uses genomics to give you and your doctor important risk information about how your individual tumor will likely behave. Valuable insights include:

- How likely you are to benefit from chemotherapy^{1,2}
- The risk of your cancer recurring^{3,4}



Genomic Testing: The Key to Knowing Your Cancer

Our genomic test:

- Analyzes your tumor tissue to provide information about how it may behave
- Identifies changes in the tumor cells that may be driving the cancer growth
- Uncovers how your tumor may respond to treatment, and the likelihood it will return in your breast or other places in your body¹⁻⁴
- Expands on the insights of a genetic test, which assesses your inherited risk for cancer



Groundbreaking Research

The association between Recurrence Score[®] result and chemotherapy benefit has been studied in over 17,000 patients, including^{1,2,5,6}:

- Patients with node-negative (N0) early-stage breast cancer
- Patients with node-positive (N1) early-stage breast cancer
- Patients from various racial and ethnic minority groups⁷



How Does It Work?

- 1** The tissue from your most recent biopsy or lumpectomy is sent to our lab for analysis. No additional procedures are required.
- 2** We send test results to your doctor.
- 3** You and your doctor review the results together.


“The Recurrence Score test provided me assurance that I needed chemotherapy. I want to share my story to make sure patients hear both sides of the experience.”

ELLIE T.
Breast cancer survivor and
Oncotype DX® Ambassador



What Can I Expect from My Test Results?

Your Recurrence Score result is reported as a single value between 0-100. A lower Recurrence Score result means your cancer is less likely to come back, so chemotherapy is less likely to benefit you. A higher Recurrence Score result means your cancer could potentially come back, so you may benefit from chemotherapy. The following example is for a node-negative patient.



How confident can I be in this average?

Averages are estimates that can vary depending on sample size; a 95% confidence interval (CI) helps you be secure that 95% of the time the group average falls within the range shown.

What does my Recurrence Score result mean?

By looking at your specific breast tumor tissue, the test predicts the chance of your breast cancer returning* and the likelihood of chemotherapy benefiting you.

*A low Recurrence Score result does not mean there is no chance that your breast cancer will return. And a high Recurrence Score result does not mean that your breast cancer will definitely return. Your treatment decisions still depend on your unique situation and personal preferences.

What is the risk that my breast cancer will return?

This percentage shows the risk that your breast cancer will return in another part of the body when treated with endocrine therapy. For premenopausal node-positive patients, this is distant recurrence at 5 years. For postmenopausal node-positive patients, this is distant recurrence or mortality at 5 years.

Will I benefit from chemotherapy?

This percentage shows how much chemotherapy will reduce the likelihood of your breast cancer coming back. It is based on patients whose Recurrence Score results were in the same range as yours.





Used by over 1.5 million patients, the Oncotype DX Breast Recurrence Score® test is the only test that has been proven to predict the benefit of chemotherapy.^{1,2,8}

Learn More About Your Insurance Coverage and Billing Options

86% of Oncotype DX Breast Recurrence Score test patients have \$0 financial responsibility.*

The Oncotype DX Breast Recurrence Score test is covered by most commercial insurance plans and Medicare, and is available to patients who are enrolled in a Medicaid program.

To get help understanding your coverage, contact our Customer Service group at:



888-ONCOTYPE (888-662-6897)
select option 2



Email:
oncotype@exactsciences.com

To learn more about insurance coverage, visit
exactsciences.com/cancer-testing/coverage

“ I put my trust in a company that uses science to provide patients like me a test to guide treatment decisions. I'm glad I did. ”

TARA H.
Breast cancer
survivor and
Oncotype DX®
Ambassador



References:

1. Albain et al. *Lancet Oncol.* 2010;11(1):55-65. 2. Paik et al. *J Clin Oncol.* 2006;24(23):3726-3734. 3. Paik et al. *N Engl J Med.* 2004;351:2817-2826. 4. Dowsett et al. *J Clin Oncol.* 2010;28:1829-1834. 5. Kalinsky et al. *N Engl J Med.* 2021;385(25):2336-2347. 6. Sparano et al. *N Engl J Med.* 2018;379(2):111-121. 7. Abdou et al. Race and Clinical Outcomes in the RxPONDER Trial: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer (SWOG S1007). San Antonio Breast Cancer Symposium. December 2022. 8. Data on file at Genomic Health, Inc.

*The numbers cited are based on historical patient billing data from 01/02/2023 to 12/29/2023. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages you to contact your insurer with questions about coverage for the Oncotype DX Breast Recurrence Score test.

Exact Sciences¹ is an in-network provider with many commercial health plans, including Aetna, Anthem, Cigna, Humana, and UnitedHealthcare.

Exact Sciences performs the services ordered and deemed medically necessary, regardless of network-provider status.

¹Genomic Health, Inc., an Exact Sciences company, is the billing entity for Oncotype® and OncoExTra® tests.

This educational piece is not designed to provide individual advice in connection with your diagnosis or treatment plan. Talk to your health care provider about such matters and whether the Oncotype DX Breast Recurrence Score test may be right for you. The actual patients shown here used the Oncotype DX Breast Recurrence Score test in making their treatment decisions with their physicians. Individual results may vary.

The Oncotype DX Breast Recurrence Score test was developed, and the performance characteristics validated by Genomic Health, Inc., a wholly-owned subsidiary of Exact Sciences Corporation following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The Oncotype DX Breast Recurrence Score test is performed at the Genomic Health Redwood City clinical laboratory. Exact Sciences clinical laboratories are accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. This test has not been cleared or approved by the US Food and Drug Administration.

**EXACT
SCIENCES®**

Oncotype DX, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, and Recurrence Score are registered trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2024 Genomic Health, Inc. All rights reserved. M-US-IBC-00995